Clinuvel Pharmaceuticals Ltd
ASX:CUV

Watchlist Manager
Clinuvel Pharmaceuticals Ltd Logo
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Watchlist
Price: 12.11 AUD 0.92%
Market Cap: 606.2m AUD
Have any thoughts about
Clinuvel Pharmaceuticals Ltd?
Write Note
Section:
 

Relative Value

The Relative Value of one CUV stock under the Base Case scenario is 18.92 AUD. Compared to the current market price of 12.11 AUD, Clinuvel Pharmaceuticals Ltd is Undervalued by 36%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CUV Relative Value
Base Case
18.92 AUD
Undervaluation 36%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

6.4
P/S
P/S
Price to Sales
6.4
vs History
98
vs Industry
49
Median 3Y
11.3
Median 5Y
14.9
Industry
7.6
Forward
6.2
More Details
17
P/E
P/E
Price to Earnings
17
vs History
98
vs Industry
7
Median 3Y
32.4
Median 5Y
44.4
Industry
22.1
Forward
16.7
More Details
16.4
P/OCF
P/OCF
Price to OCF
16.4
vs History
92
vs Industry
9
Median 3Y
22.5
Median 5Y
28.5
Industry
21.9
More Details
19.5
P/FCFE
P/FCFE
Price to FCFE
19.5
vs History
85
vs Industry
7
Median 3Y
23.9
Median 5Y
28.9
Industry
23.4
More Details
3
P/B
P/B
Price to Book Value
3
vs History
98
vs Industry
21
Median 3Y
6
Median 5Y
7.7
Industry
2.5
More Details
4.4
EV/S
EV/S
Enterprise Value to Sales
4.4
vs History
98
vs Industry
48
Median 3Y
9.5
Median 5Y
12.9
Industry
7.5
Forward
4.3
More Details
4.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
4.4
vs History
84
vs Industry
48
Median 3Y
9.7
Median 5Y
11.6
Industry
9.3
More Details
7.4
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
7.4
vs History
98
vs Industry
9
Median 3Y
17
Median 5Y
23
Industry
4.2
Forward
9.2
More Details
7.4
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
7.4
vs History
98
vs Industry
8
Median 3Y
17
Median 5Y
23
Industry
4
Forward
9.5
More Details
11.4
EV/OCF
EV/OCF
Enterprise Value to OCF
11.4
vs History
95
vs Industry
10
Median 3Y
19.5
Median 5Y
25
Industry
5.9
More Details
13.4
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
13.4
vs History
92
vs Industry
8
Median 3Y
19.7
Median 5Y
25.1
Industry
3.9
More Details
10.5
EV/IC
EV/IC
Enterprise Value to IC
10.5
vs History
98
vs Industry
14
Median 3Y
32.8
Median 5Y
60.8
Industry
4.5
More Details

Multiples Across Competitors

CUV Competitors Multiples
Clinuvel Pharmaceuticals Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Clinuvel Pharmaceuticals Ltd
ASX:CUV
606.4m AUD 6.4 17 7.4 7.4
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 027 714.7 -180 740.1 -219 476 -216 971.5
US
Abbvie Inc
NYSE:ABBV
309B USD 5.6 60.8 15.1 23.3
US
Amgen Inc
NASDAQ:AMGN
141B USD 4.3 33.3 16 30.3
US
Gilead Sciences Inc
NASDAQ:GILD
116B USD 4.1 920.3 10.2 10.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
103.5B USD 9.7 -215.8 21.3 22.3
US
Epizyme Inc
F:EPE
94.1B EUR 1 852.6 -472.7 -514.8 -501.1
AU
CSL Ltd
ASX:CSL
134.4B AUD 5.7 31.8 19.7 24.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD 5.7 16.8 15.4 17.1
US
Seagen Inc
F:SGT
39.3B EUR 17.8 -54.7 -58.8 -53
NL
argenx SE
XBRU:ARGX
36B EUR 19.3 -135.6 -109.5 -79.8
P/S Multiple
Revenue Growth P/S to Growth
AU
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Average P/S: 3 457 240.5
6.4
57%
0.1
FR
Pharnext SCA
OTC:PNEXF
38 027 714.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.6
20%
0.3
US
Amgen Inc
NASDAQ:AMGN
4.3
26%
0.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.1
10%
0.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.7
34%
0.3
US
E
Epizyme Inc
F:EPE
1 852.6
N/A N/A
AU
CSL Ltd
ASX:CSL
5.7
23%
0.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
23%
0.2
US
S
Seagen Inc
F:SGT
17.8
118%
0.2
NL
argenx SE
XBRU:ARGX
19.3
220%
0.1
P/E Multiple
Earnings Growth P/E to Growth
AU
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Average P/E: 180
17
73%
0.2
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -180 740.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
60.8
413%
0.1
US
Amgen Inc
NASDAQ:AMGN
33.3
73%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
920.3
77%
11.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -215.8
48%
N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472.7 N/A N/A
AU
CSL Ltd
ASX:CSL
31.8
65%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.8
44%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -135.6 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Average EV/EBITDA: 15
7.4
38%
0.2
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 476 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.1
29%
0.5
US
Amgen Inc
NASDAQ:AMGN
16
62%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
16%
0.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.3
43%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.8 N/A N/A
AU
CSL Ltd
ASX:CSL
19.7
42%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.4
35%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.8 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -109.5 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Average EV/EBIT: 19.3
7.4
35%
0.2
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 971.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.3
90%
0.3
US
Amgen Inc
NASDAQ:AMGN
30.3
90%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
32%
0.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.3
45%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -501.1 N/A N/A
AU
CSL Ltd
ASX:CSL
24.6
54%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.1
42%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -79.8 N/A N/A

See Also

Summary
CUV intrinsic value, competitors valuation, and company profile.
DCF Valuation
CUV stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CUV stock valuation using valuation multiples.
Wall Street Estimates
CUV price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CUV stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 210,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.